Delays to dent Byotrol’s revenues
BYOTROL, the North West company behind the effective germ-killing technology of the same name, says that while it has made continued progress with commercial partners, delays in launching some products will hit its financial figures.
The group said progress with partner Rentokil Initial and an un-named Fortune 500 company was helping it to become a “better quality, more sustainable, business”, but it had suffered some issues during the latter part of the year.
In a trading update the AIM-listed Daresbury-based company said: “There have, however, been some delays in anticipated launch dates, and additional investment of development time…These delays will have an impact on the results for the financial year ending March 31 2012.”
It said revenue for the year would be around £2m.
Chief executive Gary Millar said the company is at a “very exciting phase in its development”, and the delays had not undermined his long-term confidence in the business.
“The complex nature of the projects involved in generating more repeatable, better quality revenues, has resulted in some delays in expected launch dates and as a result our revenues for the 12 months to March 31 will be lower than expected.
“I am confident that we now have a better quality business with strong partners that will lead to sustained growth for the future.”
During the period Rentokil Initial launched a new range, UltraProtect, which is powered by Byotrol. This comprises of hand and surface sanitising products for commercial and public use, featuring a gel hand sanitiser, a foam hand sanitiser, and handy packs of hand and surface wipes.
